ESR1 and breast cancer: Pathogenic ATM and CHEK2 variants predispose carriers to a higher risk of estrogen receptor (ER)-positive BC than ER-negative BC, while variants in PALB2 and the other moderate-risk genes increase, especially, the risk of ER-negative and triple-negative BC [3,5,8].